Bradley JD et al. Long-term results of RTOG 0617: A randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC. Int J Radiat Oncol Biol Phys 2017;99(2):S105. Abstract

Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714-68. Abstract

Faivre-Finn C et al. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-Year survival update from the phase III PACIFIC trial. ESMO 2020;Abstract LBA49.

Girard N et al. Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. ESMO 2020;Abstract 1242P.

June CH et al. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med 2017;23(5):540-7. Abstract

Naidoo J et al. Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC). ASCO 2020;Abstract 9048.

Saito G et al. Real-world survey of pneumonitis/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval: A multicenter retrospective cohort study (HOPE-005/CRIMSON). ASCO 2020;Abstract 9039.

Thomas TS et al. Evaluation of the incidence of pneumonitis in United States veterans with non-small cell lung cancer receiving durvalumab following chemoradiation. ASCO 2020;Abstract 9034.